European Medicines Agency - Withdrawals of Application - Medicinal Products for Human Use - Contusugene ladenovec Gendux

Gendux Molecular Limited withdraws its marketing authorisation application for Contusugene ladenovec Gendux (contusugene ladenovec)
The European Medicines Agency has been formally notified by Gendux Molecular Limited of its decision to withdraw its application for a centralised marketing authorisation for the medicine Contususgene ladenovec Gendux (contusugene ladenovec), suspension for injection.
Contusugene ladenovec Gendux was expected to be used for the treatment of squamous cell carcinoma in head and neck cancer.

abrir aquí:
European Medicines Agency - Withdrawals of Application - Medicinal Products for Human Use - Contusugene ladenovec Gendux